**As filed with the Securities and Exchange Commission on August 5, 2021.**

**Registration No. 333-**



**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**



**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***



**EIGER BIOPHARMACEUTICALS, INC.**

**(Exact name of Registrant as specified in its charter)**



**Delaware**

**33-0971591**

**(State or other jurisdiction of**

**incorporation or organization)**

**(I.R.S. Employer**

**Identification No.)**

**2155 Park Blvd., Palo Alto, California 94306**

**(Address, including zip code, of principal executive offices)**

**(650) 272-6138**

**(Telephone number, including area code, of principal executive offices)**

**Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan**

**(Full Title of Plan)**

**David A. Cory**

**President and Chief Executive Officer**

**Eiger BioPharmaceuticals, Inc.**

**2155 Park Blvd.**

**Palo Alto, California 94306**

**(650) 272-6138**

**(Name, address, including zip code and telephone number, including area code, of agent for service)**



***Copies to:***

**Carlton Fleming**

**Sidley Austin LLP**

**555 California Street, Suite 2000**

**San Francisco, California 94104**

**(415) 772-1200**



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |
| --- | --- | --- | --- |
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



**CALCULATION OF REGISTRATION FEE**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
|  | **Amount** | **Proposed** | **Proposed** |  |  |
| **Title of Securities** | **Maximum** | **Maximum** | **Amount of** |  |
| **to be** | **Offering Price** | **Aggregate** |  |
| **to be Registered** | **Registered (1)** | **per Share (2)** | **Offering Price** | **Registration Fee** |  |
| Common Stock, $0.001 par value per share | 805,000 (2) | $7.96 (3) | $6,407,800.00 | $699.09 |  |
| Common Stock, $0.001 par value per share | 45,000 (4) | $8.52 (5) | $383,400.00 | $41.83 |  |
| Total | 850,000 |  |  | $740.92 |  |
|  |  |  |  |  |  |

1. Eiger BioPharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement to register 850,000 shares of common stock, $0.001 par value per share (“Common Stock”), for issuance under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (the “Plan”). Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.
2. Represents shares of Common Stock reserved for future issuance under the Plan.
3. Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Stock Market LLC, on August 2, 2021.
4. Represents shares of Common Stock subject to an option granted under the Plan on June 30, 2021.
5. Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act and based on the $8.52 per share exercise price of the option to purchase 45,000 shares of Common Stock granted on June 30, 2021.



**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in this Part I is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.**

The following documents previously filed with the Commission by the Registrant are incorporated herein by reference into this Registration Statement:

1. the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Commission on [March 9, 2021](http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-10k_20201231.htm);
2. the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021, filed with the Commission on [May 6, 2021](http://www.sec.gov/Archives/edgar/data/1305253/000156459021025012/eigr-10q_20210331.htm);
3. the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021, filed with the Commission on [August 5, 2021](http://www.sec.gov/ix?doc=/Archives/edgar/data/1305253/000156459021041599/eigr-10q_20210630.htm);
4. [the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 7, 2021, April 9, 2021, April 22, 2021 and June 15,](http://www.sec.gov/ix?doc=/Archives/edgar/data/1305253/000119312521191233/d130025d8k.htm) [2021; and](http://www.sec.gov/ix?doc=/Archives/edgar/data/1305253/000119312521191233/d130025d8k.htm)
5. the description of Common Stock contained in the Registrant’s Registration Statement on Form S-3, filed with the Commission on [December 18, 2020](http://www.sec.gov/Archives/edgar/data/1305253/000119312520321539/d73885ds3.htm), and any other amendment or report filed for the purpose of updating such description.

All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant has furnished, or may from time to time furnish, to the Commission is, or will be, incorporated by reference into, or otherwise included in, this Registration Statement.

**ITEM 4. DESCRIPTION OF SECURITIES.**

Not applicable.

**ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.**

Not applicable.

**ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.**

Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. The Registrant’s amended and restated certificate of incorporation as currently in effect provides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and the Registrant’s bylaws as currently in effect provide for indemnification of its directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law.

The Registrant has entered and expects to continue to enter into agreements to indemnify its directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.

The Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such.

**ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.**

Not applicable.

**ITEM 8. EXHIBITS**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Exhibit** |  |  | **Description** | | | | | | | | | | |  |
| **Number** | |  |  |  |
| 4.1 | |  | [Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s](http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex31.htm) | | | | | | | | | | |  |  |
|  |  |  | [Current Report on Form 8-K (File No. 001-36183), filed with the Commission on February 10, 2014).](http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex31.htm) | | | | | | |  | | | | |  |
| 4.2 | |  | [Amended and Restated Bylaws of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on](http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex32.htm) | | | | | | | | |  | | |  |
|  |  |  | [Form 8-K (File No. 001-36183), filed with the Commission on February 10, 2014).](http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex32.htm) | | | | | |  | | | | | |  |
| 4.3 | |  | [Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to](http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex31.htm) | | | | | | | | | | | |  |
|  |  |  | [Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36183), filed with the Commission on March 23, 2016).](http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex31.htm) | | | | | | | |  |  | | |  |
| 4.4 | |  | [Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to](http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex32.htm) | | | | | | | | | | | |  |
|  |  |  | [Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36183), filed with the Commission on March 23, 2016).](http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex32.htm) | | | | | | | |  |  | | |  |
| 4.5\* | |  | [Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on](http://www.sec.gov/Archives/edgar/data/1305253/000156459021041599/eigr-ex101_82.htm) | | | | | | | | | | | |  |
|  |  |  | [Form 10-Q (file No. 001-36183), filed with the Commission on August 5, 2021).](http://www.sec.gov/Archives/edgar/data/1305253/000156459021041599/eigr-ex101_82.htm) | | | |  | | | | | |  | |  |
| 5.1\* | |  | [Opinion of Sidley Austin LLP with respect to validity of issuance of securities.](#page8) | | |  | | | | | | | | |  |
| 23.1\* | |  | [Consent of Sidley Austin LLP (included in Exhibit 5.1).](#page8) | | | | | | | | | | | |  |
|  | |  |  |  |  | | |  | | | | | | |  |
| 23.2\* | |  | [Consent of KPMG LLP, independent registered public accounting firm.](#page10) | |  | | | | | | | | | |  |
| 24.1\* | |  | [Power of Attorney (included on the signature page of this Registration Statement).](#page6) | | | | |  | | | | | | |  |

\* Filed herewith.

**ITEM 9. UNDERTAKINGS.**

1. The Registrant hereby undertakes:
   1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
      1. To include any prospectus required by Section 10(a)(3) of the Securities Act;
      2. To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and
      3. To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by thoseparagraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

* 1. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.
  2. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

1. The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.
2. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on the 5th day of August, 2021.

**EIGER BIOPHARMACEUTICALS, INC.**

By: /s/ David A. Cory



David A. Cory

*President and Chief Executive Officer*

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below severally constitutes and appoints David Cory andSriram Ryali, and each of them acting alone, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Signature** |  |  | **Title** |  |  | **Date** |  |
| /s/ David A. Cory | | | President, Chief Executive Officer and Director | | | August 5, 2021 | | |
| David A. Cory | | | *(Principal Executive Officer)* | | |  |  |  |
| /s/ Sriram Ryali | | | Chief Financial Officer | | | August 5, 2021 | | |
| Sriram Ryali | | | *(Principal Financial and Accounting Officer)* | | |  |  |  |
| /s/ Thomas J. Dietz | | | Chairman of the Board of Directors | | | August 5, 2021 | | |
| Thomas J. Dietz | | |  |  |  |  |  |  |
| /s/ David Apelian | | | Member of the Board of Directors | | | August 5, 2021 | | |
| David Apelian | | |  |  |  |  |  |  |
| /s/ Jeffrey S. Glenn | | | Member of the Board of Directors | | | August 5, 2021 | | |
| Jeffrey S. Glenn | | |  |  |  |  |  |  |
| /s/ Evan Loh | | | Member of the Board of Directors | | | August 5, 2021 | | |
| Evan Loh | | |  |  |  |  |  |  |



|  |  |  |
| --- | --- | --- |
| /s/ Christine Murray | Member of the Board of Directors | August 5, 2021 |
| Christine Murray |  |  |
| /s/ Kim Sablich | Member of the Board of Directors | August 5, 2021 |
| Kim Sablich |  |  |
| /s/ Amit K. Sachdev | Member of the Board of Directors | August 5, 2021 |
| Amit K. Sachdev |  |  |

**Exhibit 5.1**

SIDLEY AUSTIN LLP



555 CALIFORNIA STREET

SUITE 2000

SAN FRANCISCO, CA 94104

+1 415 772 1200

+1 415 772 7400

AMERICA • ASIA PACIFIC • EUROPE

August 5, 2021

Eiger BioPharmaceuticals, Inc.

2155 Park Blvd.

Palo Alto, CA 94306

Re: 850,000 Shares of Common Stock, $0.001 par value per share

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-8 (the “Registration Statement”) being filed by Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of 850,000 shares of Common Stock, $0.001 par value per share (the “Registered Shares”), of the Company which may be issued under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan (the “Plan”).

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have examined the Registration Statement, the Company’s Amended and Restated Certificate of Incorporation and the amendments thereto, the Company’s Amended and Restated Bylaws, the Plan and the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the Plan. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

Based on the foregoing, we are of the opinion that each Registered Share that is newly issued pursuant to the Plan will be validly issued, fully paid and non-assessable when: (i) the Registration Statement, as finally amended, shall have become effective under the Securities Act; (ii) such Registered Share shall have been duly issued and delivered in accordance with the Plan; and (iii) certificates representing such Registered Share shall have been duly executed, countersigned and registered and duly delivered to the person entitled thereto against payment of the agreed consideration therefor (in an amount not less than the par value thereof) or, if any Registered Share is to be issued in uncertificated form, the Company’s books shall reflect the issuance of such Registered Share to the person entitled thereto against payment of the agreed consideration therefor (in an amount not less than the par value thereof), all in accordance with the Plan.

Sidley Austin (CA) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.

Page 2

This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.

We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Sidley Austin LLP

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 9, 2021, with respect to the consolidated financial statements of Eiger BioPharmaceuticals, Inc., incorporated herein by reference.

/s/ KPMG LLP

San Francisco, California

August 5, 2021